Nasdaq & NYSE American Low-Price Deficiency

Your stock price drops below $1. The clock starts immediately — and most management teams are not ready for what comes next.

For newly public companies and smaller public companies with limited analyst coverage, understanding how different exchanges handle low-priced securities is not a peripheral governance question. It is an operational one with real compliance, disclosure, and investor relations consequences. The rules differ materially between exchanges, the timelines are unforgiving, and a slow response compounds the problem.

Here is what every CEO and CFO of a smaller public company needs to understand — and where the disclosure gap almost always appears.

Nasdaq: the 30-day rule and what follows it

On Nasdaq, the trigger is mechanical. If your stock closes below $1.00 per share for 30 consecutive business days, Nasdaq will issue a deficiency notice. That notice formally begins a 180-calendar-day compliance period during which the stock must close at or above $1.00 for a minimum of 10 consecutive business days to regain compliance.

If the company does not regain compliance within the initial period, it may qualify for a second 180-day period — but only by transferring to the Nasdaq Capital Market tier and demonstrating it meets initial listing standards. There is no guarantee of a second window, and Nasdaq retains discretion to initiate delisting proceedings at any point if the company's broader situation deteriorates.

The deficiency notice itself is a public event. It is disclosed via an 8-K filing and press release. From the moment it is issued, your stock trades with a compliance flag visible to every institutional investor, fund manager, and retail participant following the company. That visibility matters more than most management teams initially appreciate.

NYSE American: a different framework, a harder floor

NYSE American — the exchange most commonly used by micro and small-cap companies — takes a more contextual approach than Nasdaq. Rather than a single mechanical threshold, it evaluates low price in the context of the company's broader trading profile: total market capitalisation, shareholders' equity, and overall financial condition.

That said, there is a hard floor. A stock falling below $0.10 per share will generally prompt NYSE American to move toward delisting regardless of other financial metrics. Before that point, the exchange may issue an informal warning, which creates a window for the company to present a credible remediation plan.

NYSE American will often encourage a reverse stock split to restore the share price to a range that eliminates continued scrutiny. This is not a universal rule — the exchange assesses whether the company's fundamentals support continued listing — but in practice, a reverse split is frequently the most direct path to resolving a low-price deficiency on this exchange.

The proposed $0.25 minimum — why preparation matters now

There is a proposed rule change under active consideration that would establish a $0.25 per share minimum price requirement for continued listing on certain exchanges. If adopted, companies currently trading between $0.10 and $0.25 would find themselves inside a deficiency window under the new standard — even though they are technically compliant today.

For companies in that price range, this is not a future risk to monitor. It is a scenario that warrants preparation now: modelling the reverse split ratios that would restore compliance, reviewing charter provisions affecting authorised share counts, and assessing how a split would interact with outstanding equity incentive plans and convertible securities. Waiting for the rule to be finalised before doing this analysis is the wrong sequence.

The disclosure problem that exchange compliance does not solve

The mechanics of listing standard compliance are relatively well understood. What is consistently underestimated — particularly by smaller public companies — is the investor disclosure problem that runs in parallel.

When a stock is trading at a depressed price, analyst coverage is usually thin or entirely absent. There are no earnings models being updated, no price targets being revised, and no research notes being distributed. The information vacuum is real. And into that vacuum flows speculation, short interest, and investor uncertainty — all of which can deepen the price decline and make the compliance path significantly harder.

Proactively managing your investor disclosure when you have limited analyst coverage is not a secondary consideration — it is the primary mechanism by which a smaller public company maintains market credibility during a difficult period. That means filing accurate and timely 8-Ks when material events occur, ensuring your 10-Q and 10-K filings give the market clear and complete context about business trajectory, and using investor communications to fill the role that absent research coverage is not filling on your behalf.

Companies that go quiet during a price deficiency period make the situation worse. The market reads silence as distress. A reverse split may fix the technical listing problem. It does not fix the underlying investor relations gap. Both have to be addressed in parallel.

How Finiti works with companies navigating this

This is exactly the environment Finiti is built for. We work with micro and small-cap public companies on the SEC compliance infrastructure that sits behind their periodic filings — 10-Ks, 10-Qs, and 8-Ks — and we understand that for companies with limited analyst coverage, those filings are not just a regulatory obligation. They are the primary investor communication channel.

When a company is under price pressure, the quality and timeliness of its SEC filings carry more weight than at any other point in its public life. Investors and institutional holders who cannot access research coverage will go directly to EDGAR. What they find there — and how clearly it is presented — shapes their view of the company's credibility and management's competence.

Finiti helps smaller public companies ensure their filings are accurate, compliant, and filed on time — and that the disclosure within them reflects the reality of the business clearly enough that investors do not need an analyst to interpret it. For companies in a compliance window, we also help track the disclosure obligations that attach to the deficiency period itself — including the 8-K requirements, any shareholder communication obligations, and the ongoing reporting calendar that continues regardless of what is happening with the share price.

If your company is navigating a low-price period or wants to build the disclosure infrastructure to avoid one, we are ready to help.

Subscribe to the Finiti newsletter for frequent updates → [newsletter sign-up link]

#ListingStandards #Nasdaq #NYSEAmerican #SmallCap #MicroCap #PublicCompany #InvestorRelations #SECCompliance #Finiti